Trading Update and Notice of Results

RNS Number : 5663T

Proteome Sciences PLC

26 March 2021

 

Prior to publication, the information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the UK Market Abuse Regulations. With the publication of this announcement, this information is now considered to be in the public domain.  

    26 March 2021

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Trading Update and Notice of Results

Following the Company's announcement on 25 January 2021 the Company has been progressing the year end audit and anticipates being able to announce the 2020 full year results on Thursday, 1 April 2021. The Directors of Proteome Sciences are pleased to announce that the Company now expects to report profit after tax materially higher than announced on 25 January.  This is primarily due to higher than expected royalty receipts from Thermo Scientific for the last quarter of 2020.  The annual results are still subject to finalisation of the audit and approval by the Board.

The Directors of Proteome Sciences look forward to updating shareholders on the Company's performance at the time of announcing the full results. 

For further information please contact:

Proteome Sciences plc
Dr. Mariola Soehngen, Chief Executive Officer	Tel: [phone]
Dr Ian Pike Chief Scientific Officer
Richard Dennis, Chief Commercial Officer
Allenby Capital Limited (AIM Nominated Adviser & Broker)
John Depasquale / Jeremy Porter	Tel: [phone]

About Proteome Sciences plc. ( www.proteomics.com )

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids.  SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.

 

END

 

 

MSCFFFVIVEIEFIL